Who is sponsoring NCT00298779?

NCT00298779 is sponsored by Millennium Pharmaceuticals, Inc..

What condition does NCT00298779 study?

NCT00298779 studies Tumors, Non-Hodgkins's Lymphoma.

What drugs are being tested in NCT00298779?

Interventions: omeprazole and bortezomib.

What is the status of NCT00298779?

NCT00298779 is currently COMPLETED.

Last reviewed 2008-06-04 · How we verify

An Open-Label Study to Assess the Effect of Omeprazole Administration on the Pharmacokinetics of VELCADE in Subjects With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00298779 Phase 1 COMPLETED

This is an open-label, randomized, multiple-dose, multicenter Pharmacokinetics drug-drug interaction study in patients with advanced solid tumors, including non-Hodgkin's lymphoma, who are in need of anti-tumor therapy. In addition, the impact of omeprazole on the pharmacodynamics of VELCADE will also be evaluated.

Details

Lead sponsor	Millennium Pharmaceuticals, Inc.
Phase	Phase 1
Status	COMPLETED
Enrolment	20

Conditions

Tumors
Non-Hodgkins's Lymphoma

Interventions

omeprazole and bortezomib

Primary outcomes

The investigator will determine the patient's response to VELCADE treatment following completion of Cycle 2 (Day 21). — completion of cycle 2 - Day 21

Countries

United States